Core Scientific, Inc. (CORZ)

From the record

Core Scientific, Inc.'s filings since 2021 show 19 warning events of 6 kinds: a bankruptcy or receivership notice (8-K item 1.03, 2 times, the latest 2024-01-17); a debt default or acceleration notice (8-K item 2.04, the latest 2022-12-21); a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2023-01-27); a warning not to rely on past financial statements (8-K item 4.02, 2 times, the latest 2026-03-02); an auditor change (8-K item 4.01, 4 times, the latest 2025-03-13); a late-report notice (Form NT 10-K or NT 10-Q, 6 times, the latest 2023-05-10) (its current reports).

From the record

Core Scientific, Inc.'s 6 filed years say what it did: revenue went from $60 million in fiscal 2020 to $319 million in fiscal 2025, up 39.5% a year; it rose in 3 of 5 years; the deepest fall was 50% from fiscal 2022 to fiscal 2025; net income was positive in 1 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Core Scientific, Inc.'s diluted share count shrank about 2.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 53 sales (53 under scheduled 10b5-1 plans) and 4 purchases of their own stock on the open market in the year to 2026-11-12, buying about $444 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Core Scientific, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 2 cents per dollar of everything the company owns. Leverage: it owed about 141 cents per dollar of assets, and net share issuance: its share count grew 24.3% over the year (the filed statements).

From the record

Core Scientific, Inc.'s standing among 114 graded names in its industry family: revenue of $319 million in fiscal 2025 ranks in the top 33% by size; a net margin of -90.5% ranks in the bottom 44%; revenue growth of -20.7% a year over the last 3 filed years ranks in the bottom 20% (its annual reports).

From the record

Core Scientific, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sullivan, Adam Taylor (Chief Executive Officer, as filed), filing under that title since 2024-01-25, 2.8 years (top 40% of its family); most of the 11 officers and directors filing now have filed since the record of its people begins (2024-02-02), a floor of 2.8 years the record cannot see past, so that part is not read; 17 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Core Scientific, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $311 million against no long-term debt tagged leaves 13.3% of its assets as net cash, top 32% of its family; cash from operations less capital spending is -141.3% of revenue (bottom 27%); a gross margin of 11.9% (bottom 27%) (its annual report).

From the record

Core Scientific, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -20.7% a year over the last three filed years against 39.5% over all 6, slowing (bottom 10% of its family); the newest year grew -37.5% (bottom 11%); research spending grew 15.5% a year (top 37%); capital spending grew 23.8% a year (top 45%) (its annual reports). Core Scientific, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Core Scientific, Inc.'s newest year against its own record: revenue of $319 million in fiscal 2025 came in 30.1% below the $456 million its prior three years' pace pointed to (bottom 24% of its family); net income of $289 million against a prior three-year average of $1.3 billion (top 24%); a net margin of -90.5% against losses larger than its revenue before (top 13%) (its annual reports).